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The Rosemont Criteria Can Predict the Pain Response to Pancreatic 
Enzyme Supplementation in Patients with Suspected Chronic Pancreatitis 
Undergoing Endoscopic Ultrasound
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Background/Aims: The Rosemont classiﬁ  cation system was 
designed to standardize the endosonographic assessment 
of chronic pancreatitis. To determine whether the Rosemont 
classiﬁ  cation system can predict the response to pancreatic 
enzyme supplementation in patients undergoing endo-
scopic ultrasound (EUS) evaluation of suspected chronic 
pancreatitis. Methods: Sixty-ﬁ  ve patients were included with 
abdominal pain undergoing endosonography for suspected 
chronic pancreatitis were included. Patients completed a 
questionnaire for evaluation of their abdominal pain. Group 
1 (n=13) had EUS ﬁ  ndings consistent with or suggestive of 
chronic pancreatitis. Group 2 (n=45) had EUS ﬁ  ndings that 
were normal or indeterminate in the Rosemont classiﬁ  cation 
system. Patients were given pancreatic enzyme supplemen-
tation and then given a follow-up pain questionnaire for  a 
mean of 37 days subsequent to EUS regarding the change 
in pain. Results: Group 1 patients were more likely to have 
a response to pancreatic enzymes (62% vs 24%, p= 0.012) 
and a decrease in their pain scale ratings (2.62 vs 0.29, 
p=0.01). Computed tomography ﬁ  ndings of chronic pancre-
atitis and narcotic use did not predict the response to pan-
creatic enzyme supplementation. The individual Rosemont 
criteria of hyperechoic foci with shadowing (p=0.03), lobu-
larity (p=0.02), and stranding (p=0.001) were associated 
with improvement of pain after treatment. Conclusions: The 
Rosemont classification system can identify patients who 
are more likely to have improvement in abdominal pain after 
treatment with pancreatic enzyme supplementation. (Gut 
Liver 2012;6:521-526)
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INTRODUCTION
Chronic pancreatitis is a fibro-inflammatory disease of the 
pancreas characterized by irreversible morphologic changes 
that typically cause pain and/or loss of function.
1 Pain occurs in 
80% to 90% of patients, and is considered the most important 
factor affecting quality of life.
2 Despite this, the pathophysiology 
of pain in chronic pancreatitis is poorly understood.
3 Clinically 
it is usually difficult to determine if abdominal pain is related to 
chronic pancreatitis or some other cause, such as a functional 
disorder. One of the goals of this trial was to determine if endo-
scopic ultrasound (EUS) criteria for chronic pancreatitis can help 
determine which patients’ abdominal pain will be responsive to 
pancreatic enzyme supplementation in the absence of any gold 
standard that can reliably identify chronic pancreatitis as the 
cause of any particular patients’ abdominal pain.
Pancreatic enzyme replacement therapy is often initiated for 
the treatment of pain in chronic pancreatitis. In animal studies,
4,5 
the presence of intraluminal exogenous pancreatic enzymes ap-
pear to regulate pancreatic enzyme secretion through a negative 
feedback loop. Theoretically, this may reduce pancreatic duct 
pressure and improve abdominal pain in those with chronic 
pancreatitis. Some randomized trials,
6,7 but not all,
8-10 have shown 
that abdominal pain in patients with chronic pancreatitis im-
proves with pancreatic enzyme supplementation therapy. None 
of these trials used endoscopic ultrasound to assess the presence 
and severity of chronic pancreatitis. Therefore, there is no guid-
ance as to which patients undergoing EUS for abdominal pain 
with potential chronic pancreatitis may benefit from pancreatic 
enzyme replacement therapy.
EUS is thought to be the most sensitive procedure to detect 
chronic pancreatitis.
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tis are divided into parenchymal and ductal findings.
12 Recently 
a group of experts in the field of endosonography convened in 
Rosemont, Illinois to attempt to standardize the endosonograph-
ic diagnosis of chronic pancreatitis.
13 The Rosemont classifica-
tion system categorizes patients undergoing endosonography by 
their likelihood of having chronic pancreatitis based on defined 
EUS criteria. The utility of these criteria at predicting prognosis 
and outcome of therapy in patients with chronic pancreatitis is 
unknown. The hypothesis of this study was that patients with 
abdominal pain and clinical concern for chronic pancreatitis 
were more likely to have a pain response to pancreatic enzyme 
supplementation if they met Rosemont criteria for chronic pan-
creatitis at the time of EUS. We also sought to determine which 
endosonographic criteria for chronic pancreatitis can best pre-
dict a reduction in pain with pancreatic enzyme supplementa-
tion therapy.
MATERIALS AND METHODS
This study was conducted from October 2008 to March 2010. 
It was approved by the Institutional Review Board at the Uni-
versity of Vermont. The procedures followed were in accordance 
with the Helsinki Declaration of the World Medical Association. 
Patients referred for endosonography with suspected chronic 
pancreatitis and abdominal discomfort were considered for en-
rollment. For inclusion into the study patients had to: 1) have 
intermittent or persistent abdominal pain for at least 3 months 
prior to the EUS exam, and 2) have abdominal discomfort at the 
time of EUS. Patients with an alternative diagnosis of abdomi-
nal pain (pancreatic cancer, peptic ulcer disease, choledocholi-
thiasis, duodenal obstruction) or who had undergone a previous 
trial of pancreatic enzymes were excluded. Patients younger 
than 18 years old, those who could not fill out a questionnaire, 
or those who could not provide informed consent were also 
excluded. Patients with clinical symptoms of advanced chronic 
pancreatitis (steatorrhea, and weight loss) were included. This 
study was approved by the Committee for Human Research at 
the University of Vermont.
Included patients completed a questionnaire regarding their 
pain, bowel habits and weight prior to endosonography. The 
questionnaire evaluated the presence, duration, frequency and 
severity of abdominal pain. An 11-point linear analogue scale 
(0-10) was used to assess abdominal pain severity, as has been 
used previously to evaluate pain response to pancreatic enzymes 
in patients with chronic pancreatitis.
8 Patients were asked to re-
port the worst pain they had in the preceding 24 hours. Patients 
characterized the frequency of their abdominal pain as “month-
ly”, “weekly”, “daily”, or “constantly.” They were considered to 
have intermittent pain if the pain occurred less frequently than 
daily. Medication usage, including narcotics and proton pump 
inhibitors, history of depression, alcohol consumption, abdomi-
nal computed tomography (CT) exams and the presence of ab-
normalities in serum levels of amylase and lipase were recorded. 
Patients were classified as alcohol users if they reported drink-
ing alcohol on the initial questionnaire. Patients were classified 
as alcohol abusers if they had a history of alcoholism as identi-
fied in the electronic medical record. CT exams were considered 
consistent with chronic pancreatitis if this was the impression of 
the reading radiologist.
EUS was performed by one of 2 experienced endosonog-
raphers (R.Z., E.G.) using a radial (UCT 160) echoendoscope 
(Olympus America, Melville, NY, USA) with the Prosound α10 
Premier processor (ALOKA America, Wallingford, CT, USA). The 
linear array echoendoscope (UCT 140) was also used if a fine 
needle aspiration was performed. Sedation for procedures was 
left to the discretion of the endosonographer. Endosonographic 
criteria for chronic pancreatitis were recorded at the time of 
EUS. Parenchymal endosonographic criteria for chronic pan-
creatitis included hyperechoic foci (with or without shadowing), 
lobularity (with or without honeycombing), cysts and strand-
ing. Ductal features included dilation, hyperechogenicity or ir-
regularity of the main pancreatic duct, calculi within the main 
pancreatic duct or dilation of side branches. The presence or ab-
sence of each of these criteria was recorded for each patient. Pa-
tients were then classified according to the likelihood of having 
chronic pancreatitis as per the Rosemont Classification System.
13 
This system classifies findings as consistent with chronic pan-
creatitis, suggestive of chronic pancreatitis, indeterminate for 
chronic pancreatitis or normal. We segregated our patients into 
2 groups. Group 1 had EUS findings that were consistent with 
or suggestive of chronic pancreatitis. Group 2 had EUS findings 
that were indeterminate for chronic pancreatitis or normal. 
All included patients were started on pancreatic enzyme 
supplementation (Viokase
®-16; 4 tablets with meals and 2 with 
snacks) subsequent to their EUS exam. Viokase
®-16 contains 
16,000 units of lipase, 60,000 units of protease, and 60,000 
units of amylase per tablet. A follow-up visit was then con-
ducted 1 month after initiation of therapy. Patients were queried 
regarding their response to pancreas enzyme supplementation. 
A follow-up questionnaire identical to the one completed prior 
to performance of the EUS exam was completed. Patients were 
again asked to report the worst abdominal pain they had in 
the preceding 24 hours. Medication usage, including narcotic 
intake, alcohol intake, and compliance with pancreatic enzyme 
supplementation, was assessed. Compliance with pancreatic en-
zyme supplementation was defined as ingestion of at least half 
of one month’s supply of enzyme supplementation as reported 
by the patient. Patients who felt better with pancreatic enzyme 
supplementation and had an improved abdominal pain scale 
were classified as responders. Patients that had resolution of 
abdominal pain on pancreatic enzyme supplementation were 
considered complete responders.
Statistical analysis was performed using SPSS software (SPSS 
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were used to determine significance. The entire cohort was 
analyzed with descriptive statistics for demographic data (age, 
gender), pain characteristics (severity duration, and frequency) 
medication usage (narcotics, proton pump inhibitors), alcohol 
consumption, CT evidence of pancreatitis, history of depression, 
prior elevation in serum pancreatic enzymes, and compliance 
with pancreatic enzyme supplementation. Univariate analysis 
was performed between the 2 groups using the chi-squared 
test for qualitative variables, and the independent samples t-
test for numeric data. Patients who were not compliant with 
pancreatic enzymes were included in the analysis. The primary 
question was whether patients having an EUS exam consistent 
with or suggestive of chronic pancreatitis (group 1) were more 
likely to respond to pancreatic enzyme supplementation than 
patients with a normal exam or one that was indeterminate for 
chronic pancreatitis (group 2). This question was analyzed in 
2 ways. First, it was assessed in a binary fashion with respect 
to response to pancreatic enzymes. The chi-squared test was 
used for this analysis. Second, changes in the linear analogue 
scale for abdominal pain were compared between the 2 groups. 
The Independent samples t-test was used for this analysis. The 
chi-squared test was used to analyze which individual EUS 
characteristics best predicted response to pancreatic enzyme 
supplementation. Accuracy of the individual Rosemont criteria 
was defined as true positives+true negatives divided by the true 
positives+true negatives+false positives+false negatives.
RESULTS
There were a total of 65 patients enrolled in this study. Seven 
patients were excluded, 4 due to lack of follow-up, 1 who un-
derwent cholecystectomy, and 2 with pancreaticobiliary cancer. 
There were 13 patients (22.4%) with EUS findings consistent 
with or suggestive of chronic pancreatitis as per the Rosemont 
classification system (group 1). There were 45 patients (77.6%) 
with EUS findings that were normal or indeterminate for 
chronic pancreatitis (group 2). The mean age of the cohort was 
52 and 62% were female. The presumed etiologies of chronic 
pancreatitis of patients in group 1 included alcohol (n=6), idio-
pathic (n=5), autoimmune (n=1), and medications (n=1). Table 
1 illustrates the characteristics of patients in the total cohort, 
as well as differences between patients in group 1 and group 2. 
The mean duration, frequency, and initial severity of pain were 
not significantly different between groups. Males, current alco-
hol users, patients with an elevated serum pancreatic enzyme 
prior to endoscopic ultrasound and patients with an abdominal 
CT scan consistent with chronic pancreatitis were significantly 
more likely to have EUS findings consistent with or suggestive 
of chronic pancreatitis.
The mean duration of time between the EUS and the follow-
up visit was 37 days (standard deviation, ±12). Seventy-eight 
percent of patients were compliant with pancreatic enzyme 
supplementation. A response to pancreatic enzyme supple-
mentation was defined as patient reported improvement in ab-
dominal pain at follow-up in addition to improvement of pain 
as assessed by an 11-point linear analogue scale. A complete 
response to enzyme supplementation was defined as complete 
resolution of abdominal pain at one month. Overall, 33% of 
patients had a response to pancreatic enzyme supplementa-
tion, and 22% of patients had a complete response to treatment. 









(group 1 vs 
group 2)
Mean age±SD 52 ±12.5 56±11.7 51±12.7 0.26
Gender (% female) 62% 39% 69% 0.05
Mean yr of pain
  duration±SD
3.1±4.5 2.4±2.8 3.4±4.9 0.52
Pain constant or 
 daily
85% 85% 85% 0.99
Mean initial pain±SD 5.3±2.4 5.7±2.9 5.2±2.3 0.51
History of depression 51% 62% 48% 0.38
Current alcohol use 25% 46% 18% 0.04
History of alcohol 
 abuse
29% 46% 24% 0.12
CT consistent with 
 chronic pancreatitis
29% 69% 15%   0.001
Elevated serum
 pancreatic enzyme
55% 83% 49% 0.03
Narcotic use 25% 38% 21% 0.19
Proton pump
 inhibitor use
48% 67% 43% 0.15
SD, standard deviation.
Table 2. The Rosemont Classification and Prediction of Response to the Pancreatic Enzyme Supplementation 
  Total cohort Group 1 Group 2
p-value 
(group 1 vs group 2)
OR 95% CI
Response   33% 62% 24%   0.012 4.9 1.3-18.3
Complete response 22% 46% 16% 0.02 4.7 1.2-18.1
Group 1 had endoscopic ultrasound (EUS) findings consistent with or suggestive of chronic pancreatitis. Group 2 had EUS findings that were nor-
mal or indeterminate for chronic pancreatitis.
OR, odds ratio; CI, confidence interval.524  Gut and Liver, Vol. 5, No. 4, December 2011
Patients who had EUS findings consistent with or suggestive of 
chronic pancreatitis (group 1) were significantly more likely to 
respond to pancreatic enzyme supplementation therapy (62% 
vs 24%; p=0.012; odds ratio [OR], 4.9; 95% confidence interval 
[CI], 1.3 to 18.3) (Table 2). These patients were also significantly 
more likely to have a complete response to pancreatic enzyme 
supplementation (46% vs 16%; p=0.02; OR, 4.7; 95% CI, 1.2 to 
18.1). The average decline in abdominal pain with pancreatic 
enzyme supplementation was significantly greater in group 1 
patients than in group 2 patients (2.62 vs 0.29, p=0.01). Having 
pain intermittently (less than daily), and the duration of pain 
did not predict a response to pancreas enzymes. 
CT findings consistent with chronic pancreatitis, narcotic use, 
age, gender, history of depression, and elevation in serum pan-
creatic enzymes did not predict a response to pancreatic enzyme 
supplementation (Table 3). Patients who drank alcohol were 
more likely to respond to therapy (57% vs 26%, p=0.03) in the 
overall group. Alcohol use did not predict response to pancre-
atic enzyme therapy on subgroup analysis of group 1 or group 
2 separately (group 1, p=1.0; group 2, p=0.09). A history of al-
cohol abuse was borderline statistically significantly associated 
with improvement with pancreatic enzyme supplementation in 
the overall group (50% vs 23%, p=0.05). A history of alcohol 
abuse did not predict response to pancreatic enzyme therapy 
on subgroup analysis of group 1 or group 2 separately (group 
1, p=1.0; group 2, p=0.18). Patients who took proton pump 
inhibitors in conjunction with enzyme supplementation were 
more likely to respond to supplementation in the overall group 
(48% vs 17%, p=0.01). Proton pump inhibition did not predict 
response to pancreatic enzyme therapy on subgroup analysis of 
group 1 (p=1.0), but patients in group 2 who took proton pump 
inhibitors were more likely to improve with pancreatic enzyme 
therapy (p=0.02).
Individual parenchymal (hyperechoic foci with shadow-
ing, lobularity, hyperechoic foci without shadowing, cysts and 
stranding), and ductal (main pancreatic duct calculi, irregular 
main pancreatic duct contour, dilated side branches, main pan-
creatic duct dilation, hyperechoic main pancreatic duct margin) 
EUS Rosemont criteria for chronic pancreatitis were evaluated 
for their ability to predict a response to pancreatic enzyme 
supplementation (Table 4). The parenchymal findings of hy-
perechoic foci with shadowing, lobularity and stranding were 
predictive of a response to pancreatic enzyme supplementation. 
None of the ductal findings were predictive of improvement 
with enzyme therapy.
DISCUSSION
The use of pancreatic enzyme supplementation is controver-
sial for the treatment of pain in patients with chronic pancre-
atitis.14 While abdominal pain improved in only 33% of our 
cohort that were given pancreatic enzyme supplementation, 
patients whose EUS findings were consistent with, or sugges-
tive of, chronic pancreatitis, as per the Rosemont classification 
system, were significantly more likely to respond to pancreatic 
enzyme supplementation (62% vs 24%, p=0.012), and had a 
greater reduction in pain scales (2.62 vs 0.29, p=0.01) than those 
who had a normal EUS or indeterminate findings. Also, 46% of 
patients with EUS findings consistent with or suggest of chronic 
pancreatitis had complete resolution of abdominal pain at the 
time of follow-up, and this was significantly different from pa-
tients whose EUS findings were indeterminate or normal.  
This is the first trial to evaluate whether endoscopic ultra-
sound can predict a pain response to pancreatic enzymes in 
patients suspected of having chronic pancreatitis. EUS is in-
creasingly used to evaluate chronic pancreatitis. It is the most 
Table 3. Predictors of a Pain Response to Pancreatic Enzyme Supple-
mentation 
Characteristic p-value OR 95% CI
CT consistent with chronic pancreatitis 0.11 0.4 0.1-1.2
Gender 0.11 2.5 0.8-7.7
Age 0.79 NA -8-6.1
History of depression 0.17 0.4 0.1-1.4
Pain duration 0.69 NA -3.2-2.1
Alcohol use 0.03 3.9 1.1-13.7
Alcohol abuse 0.05 0.3 0.1-1.0
Narcotic use 0.66 0.8 0.2-2.8
Elevated serum pancreatic enzyme 0.11 0.4 0.1-1.3
Proton pump inhibitor use 0.01 0.2 0.1-0.8
OR, odds ratio; CI, confidence interval; NA, not applicable.
Table 4. The Accuracy of the Individual Rosemont Criteria in Predict-
ing a Pain Response to Pancreatic Enzyme Supplementation 
Rosemont criteria Accuracy, % p-value
Parenchymal findings    
   Hyperechoic foci with shadowing 72 0.03
   Lobularity 71 0.02
   Hyperechoic foci without shadowing 55 0.15
   Cysts 67 0.32
   Stranding 74 0.001
Ductal findings    
   MPD calculi 67 0.59
   Irregular MPD contour 66 0.32
   Dilated side branches 71 0.08
   MPD dilation 69 0.15
   Hyperechoic MPD margin 67 0.38
p-values indicate whether the individual criteria were associated with 
a pain response to pancreatic enzyme supplementation.
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sensitive imaging modality for detecting pancreatic parenchy-
mal changes.
3,15 However, it can sometimes be difficult to distin-
guish EUS findings of chronic pancreatitis from normal varia-
tion in echogenicity of the pancreas, and it is not always clear 
how these findings should change patient management. Also, 
EUS exams for chronic pancreatitis are subject to interobserver 
variability.
16,17 Ideally The Rosemont classification system could 
improve identification of patients with chronic pancreatitis, and 
help guide therapy. Our study suggests that this classification 
system can identify patients more likely to respond to pancre-
atic enzyme supplementation. The parenchymal EUS criteria 
of hyperechoic foci with shadowing, lobularity and stranding 
were best at predicting a response to pancreatic enzyme supple-
mentation in our study. Ductal criteria were not able to predict 
a response to therapy. It is possible that pancreatic enzyme 
supplementation is more effective in milder chronic pancreatitis 
prior to the development of ductal changes. Prior randomized 
controlled trials evaluating the utility of pancreatic enzyme sup-
plementation in chronic pancreatitis used CT and/or endoscopic 
retrograde cholangiopancreatography to identify patients.
6-10 In 
our study CT findings consistent with chronic pancreatitis could 
not predict a response to pancreatic enzyme supplementation. 
It may be that EUS is better at detecting a population of pa-
tients with chronic pancreatitis that will benefit from pancreatic 
enzyme supplementation because it is the best imaging test to 
detect subtle changes in the pancreatic parenchyma. 
There are limitations to our study. First, medication use, and 
the clinical manifestations and pattern of pain, vary greatly 
amongst patients with suspected chronic pancreatitis. This 
complicates analysis of change in discomfort over a given time 
interval. In our study we queried patients as to the worst pain 
they had experienced in the 24 hours prior to filling out the 
questionnaire in order to minimize problems with diurnal varia-
tion in pain, and asked them to grade the frequency of their 
pain. Variation of pain at intervals greater than one day may 
have impacted our results; however this seems unlikely because 
only a minority of patients had pain less frequently than daily 
(15%), there was no differences between groups in the variation 
of pain, and the frequency of pain could not predict a response 
to enzyme therapy. Second, there is no widely accepted and 
well validated questionnaire to evaluate pain in patients with 
suspected chronic pancreatitis. We therefore decided to use a 
simple linear analogue pain scale as has been used in previous 
studies to evaluate a response to pancreatic enzyme therapy in 
patients with chronic pancreatitis.
6-8 Third, the limited sample 
size of this study makes it difficult to reliably evaluate sub-
groups (i.e., gender, substance abuse, psychiatric history, or 
cause of chronic pancreatitis and response to pancreatic enzyme 
supplementation). Fourth, our follow-up was relatively short. 
Although the study shows that EUS criteria can predict pain 
response to pancreatic enzyme supplementation in patients with 
suspected chronic pancreatitis at 1 month, long-term follow-up 
data is needed. Finally, the design of our trial allows us to assert 
only that EUS findings of chronic pancreatitis are associated 
with a short-term improvement of pain when patients are given 
pancreatic enzyme supplementation. An alternative explana-
tion to our findings could be that the natural course of pain is 
different between patients with EUS defined chronic pancreati-
tis and those with unexplained abdominal pain and a normal 
or indeterminate EUS. The fact that there was no difference 
in the frequency, duration or initial severity of pain between 
the two groups; however, would argue against this alternative 
explanation of our findings. A randomized controlled trial of 
pancreatic enzyme supplementation in patients with EUS find-
ings of chronic pancreatitis would help resolve this question. 
Even if pancreatic enzyme supplementation is not responsible 
for the difference in improvement of abdominal pain between 
the 2 groups, our study still demonstrates that EUS can identify 
patients that will have a different clinical course of abdominal 
pain.
In conclusion, when EUS is performed for abdominal pain 
with concern for chronic pancreatitis, the Rosemont classifica-
tion system can identify patients that are more likely to have 
improvement in abdominal pain after treatment with pancreatic 
enzyme supplementation. The parenchymal EUS findings of 
hyperechoic foci with shadowing, lobularity and stranding were 
able to predict improvement in abdominal pain with pancreatic 
enzyme supplementation, and could potentially be used to guide 
therapy in this patient population.
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